reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine, has unveiled its annual report, showcasing the remarkable achievements made throughout 2023.
Operating across three research hubs in Copenhagen, Leiden, and Melbourne, reNEW is dedicated to translating stem cell science into tangible therapies.
Integral to its success are partnerships with leading organizations such as Phenomics Australia and Therapeutic Innovation Australia, both members of the NCRIS Health Group.
These collaborations extend beyond achieving research excellence, encompassing active support in the transition of successful research outcomes to real-world applications, whether commercial, clinical, or societal underscoring the consortium’s commitment to impactful translational research.
Phenomics Australia iPSC derivation and gene editing facility node, led by Dr. Sara Howden, is an integral part of reNew and provides stem cell derivation and gene-editing services to researchers worldwide. Its staff generates standard and gene-edited iPSC lines in feeder-free and chemically-defined medium in a fast and cost-effective manner. The facility can also perform gene editing in already existing hPSC lines, as well as the generation of lineage-specific reporter lines.
Discover how together, we’re shaping the future of stem cell medicine. Click here to learn more.
